Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1

被引:95
作者
Gorny, Miroslaw K.
Williams, Constance
Volsky, Barbara
Revesz, Kathy
Wang, Xiao-Hong
Burda, Sherri
Kimura, Tetsuya
Konings, Frank A. J.
Nadas, Arthur
Anyangwe, Christopher A.
Nyambi, Phillipe
Krachmarov, Chavdar
Pinter, Abraham
Zolla-Pazner, Susan
机构
[1] Vet Affairs New York Harbor Healthcare Syst, Res Enhancement Award Program, New York, NY 10010 USA
[2] NYU, Sch Med, Dept Pathol, New York, NY USA
[3] NYU, Sch Med, Dept Microbiol, New York, NY USA
[4] NYU, Sch Med, Inst Environm Med, New York, NY USA
[5] Publ Hlth Res Inst, Newark, NJ 07103 USA
[6] Alpha Royal Clin, Bamenda, Cameroon
关键词
D O I
10.1128/JVI.02202-05
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3(non-B) MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V3(92UG037.8) or V3(JR-CSF) from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3(non-B) MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3(B) MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3(non-B) and the anti-V3(B) MAbs neutralized subtype B viruses with similar activities, while the anti-V3(non-B) MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3(B) MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.
引用
收藏
页码:6865 / 6872
页数:8
相关论文
共 46 条
  • [1] Infection with HIV type 1 group m non-B subtypes in individuals living in New York City
    Achkar, JM
    Burda, ST
    Konings, FAJ
    Urbanski, MM
    Williams, CAU
    Seifen, D
    Kahirimbanyi, MN
    Vogler, M
    Parta, M
    Lupatkin, HC
    Zolla-Pazner, S
    Nyambi, PN
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) : 835 - 844
  • [2] Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: Isolation of a neutralization escape variant
    Andrus, L
    Prince, AM
    Bernal, I
    McCormack, P
    Lee, DH
    Gorny, MK
    Zolla-Pazner, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (04) : 889 - 897
  • [3] [Anonymous], 1994, CELL BIOL LAB HDB
  • [4] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    Binley, JA
    Wrin, T
    Korber, B
    Zwick, MB
    Wang, M
    Chappey, C
    Stiegler, G
    Kunert, R
    Zolla-Pazner, S
    Katinger, H
    Petropoulos, CJ
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (23) : 13232 - 13252
  • [5] RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS
    BOOM, R
    SOL, CJA
    SALIMANS, MMM
    JANSEN, CL
    WERTHEIMVANDILLEN, PME
    VANDERNOORDAA, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) : 495 - 503
  • [6] CRYPTIC NATURE OF ENVELOPE V3 REGION EPITOPES PROTECTS PRIMARY MONOCYTOTROPIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM ANTIBODY NEUTRALIZATION
    BOUHABIB, DC
    RODERIQUEZ, G
    ORAVECZ, T
    BERMAN, PW
    LUSSO, P
    NORCROSS, MA
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6006 - 6013
  • [7] GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION
    BUCHACHER, A
    PREDL, R
    STRUTZENBERGER, K
    STEINFELLNER, W
    TRKOLA, A
    PURTSCHER, M
    GRUBER, G
    TAUER, C
    STEINDL, F
    JUNGBAUER, A
    KATINGER, H
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) : 359 - 369
  • [8] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [9] Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
    Cecilia, D
    Kewalramani, VN
    O'Leary, J
    Volsky, B
    Nyambi, P
    Burda, S
    Xu, S
    Littman, DR
    Zolla-Pazner, S
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (09) : 6988 - 6996
  • [10] Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein
    Coëffier, E
    Clément, JM
    Cussac, V
    Khodaei-Boorane, N
    Jehanno, M
    Rojas, M
    Dridi, A
    Latour, M
    El Habib, R
    Barré-Sinoussi, F
    Hofnung, M
    Leclerc, C
    [J]. VACCINE, 2000, 19 (7-8) : 684 - 693